Quadricistronic system comprising a homing receptor and chimeric antigen receptor for stable genetic modification of cellular immunotherapies
Provided herein are modified NK-92® cells comprising one or more nucleic acids encoding i) a homing receptor, ii) Antigen Binding Protein (ABP) or Chimeric Antigen Receptor (CAR) that specifically binds to a target antigen, iii) an Fc Receptor such as CD16 or CD16-158V, and/or iv) a cytokine, wherein the nucleic acid sequence is operably linked to a promoter. Further provided herein are modified NK-92® cells comprising one or more nucleic acids encoding i) IL-12 and/or TGF-beta trap, ii) an Antigen Binding Protein (ABP) or Chimeric Antigen Receptor (CAR) that specifically binds to a target antigen, iii) an Fc Receptor such as CD16 or CD16-158V, and/or iv) a cytokine, wherein the nucleic acid sequence is operably linked to a promoter. Also provided are compositions and kits comprising the modified NK-92® cells, as well as methods of treating cancer using the modified cells.
1. A recombinant NK-92 cell, comprising a recombinant quadricistronic nucleic acid that includes a sequence encoding a CCR7 homing receptor, a CD19CAR, a CD16.158V, and erIL-2, wherein the recombinant NK-92 cell expresses the CCR7 homing receptor, the CD19CAR, the CD16.158V, and the erIL-2 wherein surface expression of the CCR7 enables the recombinant NK-92 cell to migrate towards CCL21 and/or CCL19, wherein the NK-92 cell has American Type Culture Collection (ATCC) deposit number CRL-2407, and wherein the sequence encoding the CCR7 comprises the nucleotide sequence of SEQ ID NO:1.
2. The recombinant NK-92 cell of claim 1 , wherein the cell is contained in a medium for administration.
3. The recombinant NK-92 cell of claim 2 , wherein the medium for administration comprises human serum albumin, human plasma, and/or a serum substitute acceptable for use in human therapeutics.
4. The recombinant NK-92 cell of claim 1 , wherein the cell is cryopreserved.